BioSpace News Archive

Ceapro Inc.  (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) announced today the initiation of its Phase 1 study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.

Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced two additional Phase 3 studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ-2113 (formerly PN-235) in head-to-head comparisons against deucravacitinib, an oral TYK2 inhibitor, in patients with moderate-to-severe psoriasis.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification.

Pristine Surgical, a medical device company dedicated to making endoscopy more efficient, consistent, and safe, has accelerated the launch of its Summit™ 4K single-use surgical arthroscope—the first of its kind.

Myricx Bio is pleased to announce the publication of ground-breaking research in Nature Cell Biology1 by its collaborators at the MRC-LMS that has uncovered the central role of NMT as a druggable pathway in senescence.

Stonegate Healthcare Partners highlights a unique opportunity in its report, “Black Friday Biotech Sale: 12 Stocks for XBI-MAS.” Despite overall market health, biotech stocks have significantly declined, with the XBI biotech index 56% lower than its 5-year high, and 30% of NASDAQ-listed biotech companies trading at negative enterprise value.

The AI in cancer diagnostics market is estimated to reach around USD 2,084.34 million by 2032 to grow from USD 892.23 million in 2022, growing at a remarkable CAGR of 9.35% between 2023 and 2032.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has closed its private placement that was announced on October 18, 2023 with the issuance of 3,750,000 shares at $0.20 per share and 1,875,000 common share purchase warrants

Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) today announced that Vaxcyte has exercised its option and entered into a manufacturing rights agreement with Sutro to obtain control over the development and manufacture of cell-free extract, a key component of Vaxcyte’s pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-24 and VAX-31.

Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”) today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September 30, 2023, on Monday, December 11, 2023, after the close of the stock market.